Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD

May 18, 2024

A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.

Optimizing Biosimilar Treatment Strategies in Bone Health

May 17, 2024

The Top 5 Biosimilar Articles for the Week of May 13

May 17, 2024

Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings

May 16, 2024

Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars

May 15, 2024

Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches

May 14th 2024

By Skylar Jeremias

Article

The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.

Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More

May 13th 2024

By Cameron Santoro

Article

A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.

Jeffrey Casberg Predicts Generic, Biosimilar Competition in the Pharmaceutical Market

May 12th 2024

By Cameron Santoro

Video

Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, showcasing certain drugs that will face competition soon.

Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar

May 11th 2024

By Deana Ferreri, PhD

Article

In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.

Resources for Patients and Providers on Adalimumab Biosimilars

May 10th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars

May 10th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.

Common Questions From Patients About Adalimumab Biosimilars

May 10th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

The Top 5 Biosimilar Articles for the Week of May 6

May 10th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 6, 2024.

Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability

May 9th 2024

By Skylar Jeremias

Article

As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.

Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market

May 8th 2024

By Skylar Jeremias

Article

Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.